GlassScriptPhysician profile
Craig A Alpaugh
NPI 1851471015
$4,174.49
in general payments reported to CMS, 2019-2025
26 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $552 · 2022: $1,019 · 2023: $1,685 · 2024: $742 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,500 · Travel and Lodging: $753 · Education: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,499.61 |
| Travel and Lodging | $752.54 |
| Education | $351.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $1,379.58 | 2021-2024 | Senza |
| Scilex Pharmaceuticals INC. | $635.62 | 2021-2024 | Ztlido |
| Boston Scientific Corporation | $345.82 | 2022-2024 | Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $336.88 | 2021-2022 | |
| Abbvie INC. | $267.28 | 2021-2025 | |
| Saluda Medical Americas, INC. | $233.28 | 2023-2024 | Evoke Scs, Evoke |
| Collegium Pharmaceutical, INC. | $213.14 | 2021-2025 | Xtampza, Belbuca |
| Pfizer INC. | $165.94 | 2021-2024 | |
| Vertos Medical, INC. | $95.90 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $73.54 | 2021-2022 | |
| International Rehabilitative Sciences, INC | $58.64 | 2024-2025 | Rs 4i Plus Sequential Stimulator |
| Ibsa Pharma INC. | $51.04 | 2021-2024 | Tirosint, Licart |
| Grt US Holding, INC. | $42.00 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $37.92 | 2024-2025 | Dysport |
| Relievant Medsystems, INC. | $30.75 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $26.15 | 2024 | |
| Merz Pharmaceuticals, LLC | $24.50 | 2024 | Xeomin |
| Lilly USA, LLC | $23.46 | 2025 | Zepbound |
| Arbor Pharmaceuticals, INC. | $21.09 | 2022 | |
| Novo Nordisk INC | $19.43 | 2025 | |
| Indivior INC. | $17.55 | 2021 | |
| Horizon Therapeutics Plc | $16.66 | 2021 | |
| Stryker Corporation | $16.01 | 2023 | Multigen 2 |
| Vertex Pharmaceuticals Incorporated | $15.78 | 2025 | |
| Fidia Pharma USA INC. | $13.90 | 2021 | |
| Avanos Medical | $12.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Alpaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.